Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Four new members of the SOCS (show CISH Antibodies) family of molecules in rainbow trout (Oncorhynchus mykiss), CISH (show CISH Antibodies) and SOCS6, 7 and 9, are described for the first time in this species
Together, our data provide important evidence for miR (show MLXIP Antibodies)-19 mediated SOCS6 in OS growth and revealed miR (show MLXIP Antibodies)-19/SOCS6/JAK2 (show JAK2 Antibodies)/STAT3 (show STAT3 Antibodies) pathway as a potential therapeutic strategy for OS patients.
Results indicate that similar to PTEN pseudogene (PTENP1), suppressor of cytokine signaling 6 protein (SOCS6) expression was also significantly lower in esophageal squamous cell carcinoma (ESCC) samples.
our results describe for the first time the role of miR (show MLXIP Antibodies)-494-3p during normal hematopoietic stem/progenitor cells differentiation and suggest that its increased expression, and the subsequent downregulation of its target SOCS6, might contribute to the megakaryocyte hyperplasia commonly observed in primary myelofibrosis patients.
miR (show MLXIP Antibodies)-142-3p regulates NPC (show NPC1 Antibodies) development by down-regulating SOCS6 expression and suggest that modulation of miR (show MLXIP Antibodies)-142-3p expression could be a therapeutic strategy for NPC (show NPC1 Antibodies)
Stage-independent downregulation of SOCS2 (show SOCS2 Antibodies) and SOCS6 correlate with disease-free survival in colorectal cancer.
Studied both the function of upregulated miR (show MLXIP Antibodies)-424-5p in pancreatic cancer and how downstream suppressor of cytokine-induced signaling 6 (SOCS6) is negatively regulated by miR (show MLXIP Antibodies)-424-5p.
miR-17-5p might function as a pro-proliferative factor by repressing SOCS6 in gastric cancer
SOCS2 (show SOCS2 Antibodies) and SOCS6 expression are remarkably reduced in hepatocellular carcinoma and correlate with aggressive tumor progression and poor prognosis
Results show that SOCS6 forms complex with DRP1 (show CRMP1 Antibodies) and the mitochondrial phosphatase PGAM5 (show PGAM5 Antibodies), attenuates DRP1 (show CRMP1 Antibodies) phosphorylation, and promotes DRP1 (show CRMP1 Antibodies) mitochondrial translocation.
SOCS6 negatively regulates Flt3 (show FLT3 Antibodies) activation, the downstream Erk (show EPHB2 Antibodies) signaling pathway, and cell proliferation.
Results suggest: 1) SOCS6 and SOCS7 (show SOCS7 Antibodies) bind tyrosine-phosphorylated DAB1 (show DAB1 Antibodies) and commit it to ubiquitination and proteasomal degradation. 2) Removal of phosphorylated DAB1 (show DAB1 Antibodies) by SOCS6 and SOCS7 (show SOCS7 Antibodies) terminates reelin (show RELN Antibodies) signaling and allows a new cycle of reelin (show RELN Antibodies) signaling to commence. 3) Repeated cycles of reelin (show RELN Antibodies) signaling "ON" and "OFF" drive the fundamentally cyclic process of cell migration in the cortex.
Our results show that endogenous Cul5 (show CUL5 Antibodies) suppresses epithelial cell transformation by several pathways, including inhibition of Src (show SRC Antibodies)-Cas (show CTNND1 Antibodies)-induced ruffling through SOCS6
SOCS-6 binds to insulin receptor substrate 4 (show IRS4 Antibodies), and mice lacking the SOCS-6 gene exhibit mild growth retardation(SOCS-6)
SOCS4 expression, in contrast, does not appear to be EPO (show EPO Antibodies) inducible.SOCS4 is ineffective at counteracting EPO (show EPO Antibodies)-mediated events.
SOCS6 has a role as a negative regulator of receptor tyrosine kinases
SOCS-6 expression is induced by insulin, which regulates its binding to the p85 monomer of phosphoinositide 3-kinase
TH1 (show HAND1 Antibodies)-specific chromatin structure is created by early recruitment of Swi (show SMARCA1 Antibodies)-SNF (show SNRPA Antibodies) complexes and nucleosome remodeling dependent on Stat4 (show STAT4 Antibodies).
The protein encoded by this gene contains a SH2 domain and a CIS homolog domain. The protein thus belongs to the cytokine-induced STAT inhibitor (CIS), also known as suppressor of cytokine signaling (SOCS) or STAT-induced STAT inhibitor (SSI), protein family. CIS family members are known to be cytokine-inducible negative regulators of cytokine signaling. The expression of this gene can be induced by GM-CSF and EPO in hematopoietic cells. A high expression level of this gene was found in factor-independent chronic myelogenous leukemia (CML) and erythroleukemia (HEL) cell lines.
suppressor of cytokine signaling 6
, suppressor of cytokine signaling
, hypothetical protein LOC100124796
, STAT induced STAT inhibitor-4
, cytokine-inducible SH2 protein 4
, suppressor of cytokine signaling 4
, SH2 domain containing SOCS box protein SOCS6
, cytokine inducible SH2-containing protein 4
, cytokine inducible SH2-containing protein CIS4